UBS Group’s Bellerophon Therapeutics BLPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-2,297
| Closed | -$2.07K | – | 11553 |
|
|
2022
Q4 | $2.07K | Buy |
+2,297
| New | +$2.35K | ﹤0.01% | 9740 |
|
|
2022
Q2 | – | Sell |
-2,571
| Closed | -$6K | – | 11766 |
|
|
2022
Q1 | $6K | Buy |
2,571
+351
| +16% | +$836 | ﹤0.01% | 9076 |
|
|
2021
Q4 | $7K | Buy |
2,220
+1,049
| +90% | +$3.48K | ﹤0.01% | 9231 |
|
|
2021
Q3 | $4K | Sell |
1,171
-2,190
| -65% | -$9.13K | ﹤0.01% | 8776 |
|
|
2021
Q2 | $16K | Buy |
3,361
+1,258
| +60% | +$5.64K | ﹤0.01% | 7624 |
|
|
2021
Q1 | $11K | Buy |
2,103
+450
| +27% | +$3.13K | ﹤0.01% | 7902 |
|
|
2020
Q4 | $11K | Sell |
1,653
-477
| -22% | -$3.9K | ﹤0.01% | 7463 |
|
|
2020
Q3 | $22K | Buy |
2,130
+1,044
| +96% | +$12.3K | ﹤0.01% | 6262 |
|
|
2020
Q2 | $14K | Buy |
1,086
+192
| +21% | +$2.69K | ﹤0.01% | 6815 |
|
|
2020
Q1 | $10K | Buy |
894
+60
| +7% | +$402 | ﹤0.01% | 6966 |
|
|
2019
Q4 | $4K | Buy |
+834
| New | +$5.3K | ﹤0.01% | 7715 |
|
|
2019
Q3 | – | Sell |
-733
| Closed | -$7K | – | 8483 |
|
|
2019
Q2 | $7K | Sell |
733
-553
| -43% | -$5.3K | ﹤0.01% | 7287 |
|
|
2019
Q1 | $13K | Buy |
1,286
+19
| +1% | +$209 | ﹤0.01% | 6666 |
|
|
2018
Q4 | $15K | Buy |
1,267
+189
| +18% | +$2.74K | ﹤0.01% | 7010 |
|
|
2018
Q3 | $17K | Buy |
1,078
+972
| +917% | +$23.1K | ﹤0.01% | 6904 |
|
|
2018
Q2 | $4K | Sell |
106
-305
| -74% | -$10.6K | ﹤0.01% | 7595 |
|
|
2018
Q1 | $13K | Buy |
+411
| New | +$13.1K | ﹤0.01% | 6740 |
|
|
2017
Q3 | – | Sell |
-671
| Closed | -$13K | – | 8163 |
|
|
2017
Q2 | $13K | Buy |
+671
| New | +$13.9K | ﹤0.01% | 6618 |
|
|
2016
Q4 | – | Sell |
-618
| Closed | -$13K | – | 8201 |
|
|
2016
Q3 | $13K | Buy |
618
+567
| +1,112% | +$13.7K | ﹤0.01% | 6627 |
|
|
2016
Q2 | $1K | Sell |
51
-29
| -36% | -$795 | ﹤0.01% | 7602 |
|
|
2016
Q1 | $3K | Buy |
80
+18
| +29% | +$667 | ﹤0.01% | 7242 |
|
|
2015
Q4 | $3K | Sell |
62
-363
| -85% | -$17.6K | ﹤0.01% | 7927 |
|
|
2015
Q3 | $33K | Buy |
425
+382
| +888% | +$29.4K | ﹤0.01% | 6218 |
|
|
2015
Q2 | $5K | Sell |
43
-54
| -56% | -$7.34K | ﹤0.01% | 7903 |
|
|
2015
Q1 | $13K | Buy |
+97
| New | +$15.1K | ﹤0.01% | 7452 |
|
Other funds holding BLPH
UBS Group's BLPH Position: Q1 2023 in Review
UBS Group sold out of Bellerophon Therapeutics (BLPH) in Q1 2023, closing a stake of 2,297 shares — an estimated $2.07K sold.
UBS Group first reported a position in BLPH in Q1 2015 and held it in 25 quarters. The position peaked at $33K in Q3 2015. 19 funds tracked by Wall St. Rank hold BLPH as of Q1 2023.
- UBS Group reported no remaining Bellerophon Therapeutics position as of Q1 2023 after selling out during the quarter.
- UBS Group sold 2,297 Bellerophon Therapeutics shares in Q1 2023, an estimated $2.07K.
- UBS Group first reported a position in Bellerophon Therapeutics in Q1 2015 and held it in 25 quarters.
- UBS Group's Bellerophon Therapeutics position peaked at $33K in Q3 2015.
- 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics as of Q1 2023.
Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.